- Last edited on February 25, 2022
Daridorexant (Quviviq)
Primer
Daridorexant (Trade name: Quviviq) is a dual orexin receptor antagonist (DORA) used in the treatment of insomnia disorder.
Pharmacokinetics
See also article: Introduction to Pharmacology
Pharmacokinetics of Daridorexant
See also article: Cytochrome (CYP) P450 Metabolism
Daridorexant: Cytochrome P450 Metabolism
Substrate of (Metabolized by) | |
---|---|
Induces | |
Inhibits |
Pharmacodynamics
Mechanism of Action
Toxicity
Indications
Dosing
Dosing for Daridorexant
Starting | 25 mg PO daily |
---|---|
Titration | |
Maximum | 50 mg PO daily |
Taper |
Formulations
- Daridorexant comes in
Monitoring
Contraindications
Absolute
Relative
Drug-Drug Interactions
Side Effects
Adverse Events
Clinical Pearls
-
- Patients with a history of abuse or addiction may be at increased risk for abuse and addiction to DORAs and should be followed carefully
Special Populations
Geriatric
See main article: Geriatric Pharmacology
Pediatric
See main article: Pediatric Pharmacology
Obstetric and Fetal
See main article: Obstetric and Fetal Pharmacology
Medically Ill
See main article: Psychotropic Dosing in the Medically Ill